TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
TG Therapeutics reported strong Q3 2024 financial results with BRIUMVI net revenue of $83.3 million, representing 15% quarter-over-quarter growth and 230% year-over-year increase. The company raised its full-year 2024 BRIUMVI revenue guidance to $300-305 million. Clinical data showed impressive 5-year results with 92% of patients free from disability progression and an annualized relapse rate of 0.02. The company secured FUJIFILM Diosynth as a secondary US manufacturer and reported Q3 net income of $3.9 million with a strong cash position of $341 million.
TG Therapeutics ha riportato risultati finanziari solidi per il terzo trimestre del 2024 con un fatturato netto di BRIUMVI di 83,3 milioni di dollari, che rappresenta una crescita del 15% rispetto al trimestre precedente e un aumento del 230% rispetto all'anno precedente. L'azienda ha alzato la sua previsione di fatturato per il BRIUMVI per l'intero anno 2024 a 300-305 milioni di dollari. I dati clinici hanno mostrato risultati notevoli a 5 anni, con il 92% dei pazienti liberi dalla progressione della disabilità e un tasso annualizzato di ricadute di 0,02. L'azienda ha consolidato FUJIFILM Diosynth come produttore secondario negli Stati Uniti e ha riportato un reddito netto nel terzo trimestre di 3,9 milioni di dollari, con una solida posizione di cassa di 341 milioni di dollari.
TG Therapeutics reportó sólidos resultados financieros para el tercer trimestre de 2024 con un ingreso neto de BRIUMVI de 83.3 millones de dólares, lo que representa un crecimiento del 15% en comparación con el trimestre anterior y un aumento del 230% en comparación con el año anterior. La compañía elevó su pronóstico de ingresos para BRIUMVI para todo el año 2024 a 300-305 millones de dólares. Los datos clínicos mostraron resultados impresionantes a 5 años, con el 92% de los pacientes libres de progresión de discapacidad y una tasa de recaída anualizada de 0,02. La compañía aseguró a FUJIFILM Diosynth como fabricante secundario en EE. UU. y reportó un ingreso neto en el tercer trimestre de 3.9 millones de dólares, con una sólida posición de efectivo de 341 millones de dólares.
TG Therapeutics는 2024년 3분기 강력한 재무 실적을 보고했으며, BRIUMVI의 순수익이 8,330만 달러로 나타났습니다. 이는 전 분기 대비 15% 증가하고, 전년 대비 230% 증가한 수치입니다. 회사는 2024년 전체 BRIUMVI 수익 전망을 3억~3억 5백만 달러로 상향 조정했습니다. 임상 데이터는 5년 동안 92%의 환자가 장애 진행 없이 지냈고, 연환산 재발율이 0.02라는 인상적인 결과를 보여주었습니다. 이 회사는 FUJIFILM Diosynth를 미국의 2차 제조업체로 확보하였고, 3분기 순이익 390만 달러를 기록했으며, 강력한 현금 보유액 3억 4,100만 달러를 보고했습니다.
TG Therapeutics a annoncé des résultats financiers solides pour le troisième trimestre 2024 avec un chiffre d'affaires net de BRIUMVI de 83,3 millions de dollars, représentant une croissance de 15 % par rapport au trimestre précédent et une augmentation de 230 % par rapport à l'année précédente. L'entreprise a relevé son objectif de chiffre d'affaires pour BRIUMVI pour l'année 2024 à 300-305 millions de dollars. Les données cliniques ont montré des résultats impressionnants sur 5 ans, avec 92 % des patients exempts de progression de l'invalidité et un taux de rechute annualisé de 0,02. L'entreprise a réussi à obtenir FUJIFILM Diosynth comme fabricant secondaire aux États-Unis et a rapporté un revenu net de 3,9 millions de dollars pour le troisième trimestre avec une solide position de trésorerie de 341 millions de dollars.
TG Therapeutics berichtete über starke finanzielle Ergebnisse für das dritte Quartal 2024 mit einem Nettoumsatz von BRIUMVI in Höhe von 83,3 Millionen Dollar, was einem Wachstum von 15 % im Vergleich zum Vorquartal und einem Anstieg von 230 % im Vergleich zum Vorjahr entspricht. Das Unternehmen hob seine Umsatzprognose für BRIUMVI für das gesamte Jahr 2024 auf 300-305 Millionen Dollar an. Klinische Daten zeigten beeindruckende Ergebnisse über 5 Jahre, mit 92 % der Patienten, die frei von einer Behinderungsprogression waren und einer annualisierten Rückfallrate von 0,02. Das Unternehmen sicherte sich FUJIFILM Diosynth als sekundären Hersteller in den USA und meldete einen Nettogewinn von 3,9 Millionen Dollar für das dritte Quartal mit einer starken Barposition von 341 Millionen Dollar.
- BRIUMVI Q3 revenue grew 230% YoY to $83.3 million
- Raised full-year revenue guidance to $300-305 million
- Strong cash position of $341 million
- Positive net income of $3.9 million in Q3 2024
- Secured secondary US manufacturer for BRIUMVI
- R&D expenses increased to $20.1 million in Q3 2024 from $14.8 million in Q3 2023
- SG&A expenses rose to $42.0 million from $32.8 million YoY
- License revenue decreased significantly YoY from $140.7 million to $0.6 million in Q3
Insights
TGTX delivered a strong Q3 with
Key financial metrics show operational leverage improving, though SG&A expenses increased to
The 5-year ULTIMATE I & II trial data significantly strengthens BRIUMVI's clinical profile, with
Pipeline expansion into subcutaneous administration and progression into new autoimmune indications, coupled with the FDA clearance for azer-cel in progressive MS, indicates strong development momentum. The addition of FUJIFILM as a secondary manufacturer reduces supply chain risks.
Third quarter 2024 U.S. BRIUMVI net revenue of
Raises full year 2024 U.S. BRIUMVI net revenue target to
Conference call to be held today, November 4, 2024, at 8:30 AM ET
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance.
Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to share with you the results of another quarter of growth and execution of our BRIUMVI launch and pipeline development. With
Recent Highlights & Developments
United States (U.S.) Commercialization of BRIUMVI® (ublituximab-xiiy)
- BRIUMVI U.S. net product revenue of
$83.3 million for the third quarter of 2024, reflecting approximately15% quarter-over-quarter growth and over230% growth from the same quarter last year
BRIUMVI Clinical Data Presentations
- Presented updated data at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting including:
- New five year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis (RMS) which demonstrated that
92% of patients were free from disability progression after five years of treatment, an annualized relapse rate of 0.02 during year 5 of treatment (equivalent to one relapse occurring every fifty years of patient treatment), and an overall safety profile which remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment. - New data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with RMS which demonstrated that:
- Rapid 30-minute BRIUMVI infusions are well tolerated with all infusion related reactions being mild (Grade 1) and resolving completed, and
- RMS patients who are already B-cell depleted can safely switch from a prior anti-CD20 therapy directly to 450 mg of BRIUMVI administered in 1 hour as an initial infusion, without a 150 mg initial dose, with
97% of infusions being completed without interruption or slowing.
- New five year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis (RMS) which demonstrated that
Pipeline
- Initiated a phase 1 clinical trial evaluating subcutaneous ublituximab in RMS
- Received clearance by the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application for azer-cel in progressive forms of multiple sclerosis (MS)
Manufacturing
- Secured FUJIFILM Diosynth Biotechnologies as a secondary US-based manufacturer of BRIUMVI out of its Holly Spring, North Carolina, United States, based facility.
2024 Updated Target U.S. BRIUMVI Guidance
- Raising BRIUMVI U.S. net product revenue target to
$300 t o$305 million for the full year 2024 (prior guidance of$290 t o$300 million for full year 2024)
Remaining 2024 Development Pipeline Anticipated Milestones
- Study BRIUMVI in an additional autoimmune disease outside of MS
- Commence a clinical trial evaluating azer-cel in autoimmune diseases, starting with progressive MS
Financial Results for Third Quarter 2024
- Product Revenue, net: Product revenue, net was approximately
$83.3 million and$206.4 million for the three and nine months ended September 30, 2024, respectively, compared to$25.1 million and$48.9 million for the three and nine months ended September 30, 2023, respectively. Product revenue, net for both the three and nine months ended September 30, 2024, and 2023, consisted of net product sales of BRIUMVI in the United States. - License, milestone, royalty and other revenue: License, milestone, royalty and other revenue was approximately
$0.6 million and$14.4 million for the three and nine months ended September 30, 2024, respectively, compared to$140.7 million and$140.8 million for the three and nine months ended September 30, 2023, respectively. License, milestone, royalty and other revenue for the nine months ended September 30, 2024, is predominantly comprised of a$12.5 million milestone payment under the Neuraxpharm Commercialization Agreement for the first key market commercial launch of BRIUMVI in the European Union (EU) which occurred in the first quarter of 2024. License, milestone, royalty and other revenue for the nine months ended September 30, 2023 is predominantly comprised of recognition of the one-time$140.0 million non-refundable upfront payment under the Commercialization Agreement with Neuraxpharm. - R&D Expenses: Total research and development (R&D) expense was approximately
$20.1 million and$70.4 million for the three and nine months ended September 30, 2024, respectively, compared to$14.8 million and$58.7 million for the three and nine months ended September 30, 2023, respectively. The increase in R&D expense during the three and nine months ended September 30, 2024 was primarily attributable to license and milestone expense related to the license agreement with Precision BioSciences, Inc., as well as additional manufacturing and development costs incurred in connection with our ublituximab subcutaneous development work during the period. - SG&A Expenses: Total selling, general and administrative (SG&A) expense was approximately
$42.0 million and$115.3 million for the three and nine months ended September 30, 2024, respectively, compared to$32.8 million and$91.6 million for the three and nine months ended September 30, 2023, respectively. The increase in both periods was primarily due to other selling, general and administrative costs, including personnel and consultants, associated with the commercialization of BRIUMVI during the period ended September 30, 2024. - Net Income: Net income was
$3.9 million and$0.1 million for the three and nine months ended September 30, 2024, respectively, compared to net income of$113.9 million and$27.1 million for the three and nine months ended September 30, 2023, respectively. - Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were
$341.0 million as of September 30, 2024. We anticipate that our cash, cash equivalents and investment securities as of September 30, 2024, combined with the projected revenues from BRIUMVI, will be sufficient to fund our business based on our current operating plan.
CONFERENCE CALL INFORMATION
The Company will host a conference call today, November 4, 2024 at 8:30 AM ET to discuss the Company’s financial results from the third quarter ended September 30, 2024.
To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live audio webcast will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. An audio recording of the conference call will also be available for a period of 30 days after the call.
ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.
BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and UK for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.
A list of authorized specialty distributors can be found at www.briumvi.com.
IMPORTANT SAFETY INFORMATION
Contraindications: BRIUMVI is contraindicated in patients with:
- Active Hepatitis B Virus infection
- A history of life-threatening infusion reaction to BRIUMVI
WARNINGS AND PRECAUTIONS
Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was
Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.
Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was
Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.
Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.
Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JC virus infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies.
If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.
If PML is confirmed, treatment with BRIUMVI should be discontinued.
Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.
Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.
Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.
Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in
Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least
Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.
The full Summary of Product Characteristics approved in the European Union (EU) for BRIUMVI can be found here Briumvi | European Medicines Agency (europa.eu).
ABOUT BRIUMVI PATIENT SUPPORT in the U.S.
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.
ABOUT MULTIPLE SCLEROSIS
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.
Such forward looking statements include but are not limited to statements regarding expectations for the timing and success of the ongoing commercialization and availability of BRIUMVI® (ublituximab-xiiy) for RMS in the United States and Europe; anticipated healthcare professional (HCP) and patient acceptance and use of BRIUMVI for the approved indications; expectations of future revenue for BRIUMVI, expenses, or profits; expectations for our pipeline products; ; and the results of the ENHANCE or ULTIMATE I & II Phase 3 studies.
Additional factors that could cause our actual results to differ materially include the following: the Company’s ability to maintain and continue to maintain a commercial infrastructure for BRIUMVI, and to successfully, or in the timeframe projected, market and sell BRIUMVI; the risk that trends in prescriptions are not maintained or that prescriptions are not filled; the failure to obtain and maintain payor coverage; the risk that HCP interest in BRIUMVI will not be sustained; the risk that momentum in sales for BRIUMVI will not build during the course of the year; the risk that the commercialization of BRIUMVI does not continue to exceed expectations; the risk that our current or future BRIUMVI revenue targets will not be achieved; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, the potential for variation from the Company’s projections and estimates about the potential market for BRIUMVI due to a number of factors, including, further limitations that regulators may impose on the required labeling for BRIUMVI (such as modifications, resulting from safety signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials); the Company’s ability to meet post-approval compliance obligations (on topics, including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); the Company’s reliance on third parties for manufacturing, distribution and supply, and other support functions for our clinical and commercial products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; potential regulatory challenges to the Company’s plans to seek marketing approval for the product in jurisdictions outside of the U.S.; the uncertainties inherent in research and development; the risk that any individual patient’s clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that the Company does not achieve its 2024 development pipeline anticipated milestones in the timeframe projected or at all, including the development of subcutaneous BRIUMVI, commencing a trial evaluating BRIUMVI in an autoimmune disease outside of MS, or commencing a trial evaluating azer-cel; and general political, economic, and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our other filings with the SEC.
Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor p. 236.
TG Therapeutics, Inc. | |||||||||
Selected Condensed Consolidated Financial Data | |||||||||
Statements of Operations Information (in thousands, except share and per share amounts; unaudited): | |||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||
2024 | 2023 | 2024 | 2023 | ||||||
Revenue | |||||||||
Product revenue, net | 83,297 | 25,068 | 206,381 | 48,868 | |||||
License, milestone, royalty and other revenue | 582 | 140,747 | 14,438 | 140,823 | |||||
Total revenue | 83,879 | 165,815 | 220,819 | 189,691 | |||||
Costs and expenses: | |||||||||
Cost of revenue | 9,341 | 3,509 | 23,087 | 6,277 | |||||
Research and development: | |||||||||
Noncash compensation | 3,028 | 2,915 | 8,000 | 10,162 | |||||
Other research and development | 17,110 | 11,838 | 62,417 | 48,581 | |||||
Total research and development | 20,138 | 14,753 | 70,417 | 58,743 | |||||
Selling, general and administrative: | |||||||||
Noncash compensation | 8,745 | 6,269 | 22,593 | 18,386 | |||||
Other selling, general and administrative | 33,221 | 26,500 | 92,742 | 73,167 | |||||
Total selling, general and administrative | 41,966 | 32,769 | 115,335 | 91,553 | |||||
Total costs and expenses | 71,445 | 51,031 | 208,839 | 156,573 | |||||
Operating income | 12,434 | 114,784 | 11,980 | 33,118 | |||||
Other expense (income): | |||||||||
Interest expense | 10,832 | 3,713 | 16,967 | 10,184 | |||||
Other income | (2,666 | ) | (2,859 | ) | (5,128 | ) | (4,154 | ) | |
Total other expense , net | 8,166 | 854 | 11,839 | 6,030 | |||||
Net income before taxes | |||||||||
Income tax expense | 388 | - | 89 | - | |||||
Net Income | |||||||||
Net income per common share: | |||||||||
Basic | |||||||||
Diluted | |||||||||
Weighted average shares of common stock outstanding | |||||||||
Basic | 145,102,479 | 142,871,227 | 145,342,337 | 141,571,785 | |||||
Diluted | 160,714,388 | 155,871,749 | 160,366,927 | 145,952,913 |
Condensed Balance Sheet Information (in thousands): | ||
September 30, 2024 (Unaudited) | December 31, 2023* | |
Cash, cash equivalents and investment securities | 341,041 | 217,508 |
Total assets | 586,014 | 329,587 |
Total equity | 192,157 | 160,502 |
* Condensed from audited financial statements |
FAQ
What was BRIUMVI's Q3 2024 revenue for TG Therapeutics (TGTX)?
What is TG Therapeutics' (TGTX) updated revenue guidance for BRIUMVI in 2024?
What were the 5-year clinical results for BRIUMVI presented at ECTRIMS 2024?